Archives of Medical Research最新文献_第2页

Improving Efficiency in Healthcare: Lessons from Successful Health Policies in Chile 提高医疗保健效率：智利成功医疗政策的经验教训

IF 4.7 3区医学

Archives of Medical Research Pub Date : 2024-10-17 DOI: 10.1016/j.arcmed.2024.103105

{"title":"Improving Efficiency in Healthcare: Lessons from Successful Health Policies in Chile","authors":"","doi":"10.1016/j.arcmed.2024.103105","DOIUrl":"10.1016/j.arcmed.2024.103105","url":null,"abstract":"<div><h3>Background</h3><div>Chile has made significant progress in recent decades in implementing policies to improve the efficiency of its health system with an impact on population health.</div></div><div><h3>Aim</h3><div>To present five case studies of successful policies whose impact has been documented.</div></div><div><h3>Methods</h3><div>Case study report.</div></div><div><h3>Results</h3><div>First, we present a summary of the evidence supporting the policy that is changing the Chilean care model from a problem-based to a patient-centered care model. Second, we show how tele-nephrology and advanced renal care units have demonstrated significant impact on chronic kidney disease in Chile. This internationally recognized successful Chilean policy is contributing to address one of the conditions that explains the highest financial burden on the health system. Third, we present recent evidence on the effectiveness of teleoncology care in Chile. Fourth, we highlight the most recent system of epidemiological surveillance implemented in Chile, the EPIVIGILA system, which was essential to support decisions throughout the pandemic. Finally, we underline the health benefit plans implemented in recent decades to improve access to services and financial protection.</div></div><div><h3>Conclusions</h3><div>Chile has successfully implemented policies in its health system that have an impact on efficiency and population health. These experiences can be replicated in countries facing similar challenges, using the Chilean experience as a benchmark.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142445450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low muscle mass in the internal medicine ward: Prevalence and survival implications 内科病房的低肌肉质量：发病率和对生存的影响

IF 4.7 3区医学

Archives of Medical Research Pub Date : 2024-10-15 DOI: 10.1016/j.arcmed.2024.103103

{"title":"Low muscle mass in the internal medicine ward: Prevalence and survival implications","authors":"","doi":"10.1016/j.arcmed.2024.103103","DOIUrl":"10.1016/j.arcmed.2024.103103","url":null,"abstract":"<div><h3>Background</h3><div>Low muscle mass is common in hospitalized patients. It is associated with adverse clinical outcomes. Reported prevalence varies widely due to non-universally accepted diagnostic criteria and the heterogeneity of the populations studied. Non-surgical ill patients are underrepresented in the literature.</div></div><div><h3>Aims</h3><div>To estimate the prevalence of low muscle index and its impact on survival in patients admitted to an internal medicine unit.</div></div><div><h3>Methods</h3><div>We prospectively enrolled patients with abdominal CT scans on admission to the Internal Medicine ward. We assessed muscle mass index (L3MI) at the level of the L3 lumbar vertebra. The primary outcome was to estimate the prevalence of low muscle mass on admission. Secondary outcomes were to determine the relationship of low L3MI with hospital mortality, length of stay, nosocomial infections, and hospital readmission.</div></div><div><h3>Results</h3><div>One hundred and seven patients were included. The prevalence of low L3MI was 46.7%. An L3MI of 46.3 cm<sup>2</sup>/m<sup>2</sup> in men and 40.9 cm<sup>2</sup>/m<sup>2</sup> in women predicted death at one year with a sensitivity of 66% and a specificity of 78% (AUC = 0.62 [95% CI 0.38–0.86]) and 69 and 66% (AUC of 0.63 [95% IC 0.47–0.78]), respectively. In-hospital mortality, death at 60, 90, and 360 d, and hospital readmission were significantly higher in patients with low L3MI.</div></div><div><h3>Conclusion</h3><div>Almost half of the patients admitted to an internal medicine ward have low muscle mass index. The cutoff point of 40.9 cm<sup>2</sup>/m<sup>2</sup> in females and 46.3 cm<sup>2</sup>/m<sup>2</sup> in males predicts relevant clinical variables. We established the better L3MI cutoff value to predict 12-month mortality.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142432020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 policy response: Perspectives of key stakeholders in Mexico's health system and implications for resilience COVID-19 政策回应：墨西哥卫生系统主要利益攸关方的观点及其对复原力的影响

IF 4.7 3区医学

Archives of Medical Research Pub Date : 2024-10-15 DOI: 10.1016/j.arcmed.2024.103097

{"title":"COVID-19 policy response: Perspectives of key stakeholders in Mexico's health system and implications for resilience","authors":"","doi":"10.1016/j.arcmed.2024.103097","DOIUrl":"10.1016/j.arcmed.2024.103097","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aims to analyze the perspectives of key stakeholders within Mexico's health system regarding the policy response to COVID-19 in 2020 to inform future policy formulation.</div></div><div><h3>Methods</h3><div>This qualitative study is based on a secondary data analysis (SDA) derived from a broader primary research on governance in Mexico during the COVID-19 pandemic. The analysis adopted a grounded theory approach to examine 15 semi-structured interviews with prominent figures in the health system between June and November 2020. The interviews were audio-recorded and analyzed through the lens of the Health Policy Triangle which includes context, key actors, and the Mexican health policy process. Moreover, the analysis was enriched by incorporating the framework outlined in the World Health Organization's COVID-19 Strategic Preparedness and Response Plan (SPRP).</div></div><div><h3>Results</h3><div>The findings indicate that key stakeholders perceived a centralized approach to policymaking with a strong emphasis on cross-sector communication, expert panels, equity-focused measures, accessibility to healthcare services (promoting portability), and improvements in the health information system.</div></div><div><h3>Conclusion</h3><div>Key stakeholders recognized the response to COVID-19 was complex, involving multiple dimensions and levels of action. The importance of preparedness and response in building health system resilience is emphasized. Recommendations include explicitly integrating resilience into national and local policy agendas, addressing systemic structural deficiencies, promoting equity in the pandemic response, improving risk governance, strengthening coordination mechanisms, ensuring supply chain resilience, improving personnel training, and enhancing local diagnostic capacity to better prepare for future public health emergencies.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142432021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post COVID-19: Advancing medical laboratory service integration in nigeria and progress towards establishing integration guideline 后 COVID-19：推进尼日利亚医学实验室服务一体化以及在制定一体化准则方面取得的进展

IF 4.7 3区医学

Archives of Medical Research Pub Date : 2024-10-14 DOI: 10.1016/j.arcmed.2024.103094

{"title":"Post COVID-19: Advancing medical laboratory service integration in nigeria and progress towards establishing integration guideline","authors":"","doi":"10.1016/j.arcmed.2024.103094","DOIUrl":"10.1016/j.arcmed.2024.103094","url":null,"abstract":"<div><h3>Background</h3><div>The Nigerian healthcare system, including medical laboratories, operates in a three-tiered structure across public and private sectors. Lessons from COVID-19 show the urgent need for a guideline to drive medical laboratory service integration.</div></div><div><h3>Problem</h3><div>Lack of operational guideline to drive the integration of laboratory services has resulted in siloed operations across different medical laboratories causing duplication of resources, coordination issues, and inefficiencies.</div></div><div><h3>Aim</h3><div>To highlight the development processes of medical laboratory service integration guideline and discuss its key provisions.</div></div><div><h3>Method</h3><div>The Medical Laboratory Services Division (MLSD), Federal Ministry of Health (FMoH) initiated the development of a national guideline for integrating medical laboratory services. Partnering with stakeholders and engaging two consultants, a technical workshop was facilitated in January 2024. The Consultants garnered the initial inputs stakeholders made at the five-day meeting. The inputs were collated and organized to produce the guideline. The guideline was circulated to participants and other stakeholders for review and feedback received was used to finalize the document. The MLSD with support from partners further held a three-day stakeholders’ meeting in May 2024 to validate the document before submitting it to the Health Minister for endorsement.</div></div><div><h3>Result</h3><div>The guideline sets standards for achieving medical laboratory services and systems integration across different medical laboratories. The contents of the guideline are enumerated and respective recommendations made under each element are highlighted.</div></div><div><h3>Conclusion</h3><div>The implementation of the guideline will help harmonize services, improve access to diagnostics, streamline processes, reduce redundancies, optimize resource utilization, enhance communication, data sharing, and pandemic preparedness.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142433341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Masseter Muscle Volume and Its Association with Sarcopenia and Muscle Determinants in Older Japanese Adults: the Bunkyo Health Study 日本老年人的肌肉量及其与肌肉疏松症和肌肉决定因素的关系：文化健康研究

IF 4.7 3区医学

Archives of Medical Research Pub Date : 2024-10-14 DOI: 10.1016/j.arcmed.2024.103095

{"title":"Masseter Muscle Volume and Its Association with Sarcopenia and Muscle Determinants in Older Japanese Adults: the Bunkyo Health Study","authors":"","doi":"10.1016/j.arcmed.2024.103095","DOIUrl":"10.1016/j.arcmed.2024.103095","url":null,"abstract":"<div><h3>Aim</h3><div>Sarcopenia has been with a decrease in masseter muscle (MM) thickness in high-risk older populations. However, the relationship between sarcopenia and determinants of MM volume (MMV) in the general elderly population remains unclear.</div></div><div><h3>Method</h3><div>In a cross-sectional study of 1,484 older adults in Tokyo, we evaluated MMV using 3D MRI scanning, appendicular skeletal muscle mass (ASMM), handgrip strength, dietary intake, smoking, insulin-like growth factor 1 (IGF-1) levels, and the ACTN3 R577X polymorphism. Participants were divided into quintiles based on MMV (<em>Q1</em>–5).</div></div><div><h3>Results</h3><div>Participants in our study had a mean age of 73.0 ± 5.3 years and their MMV (Men: 35.3 ± 7.8 mL, Women: 25.0 ± 5.1 mL) was significantly higher in men than in women. A significant association between MMV and sarcopenia was observed, with the lowest quintile (<em>Q1</em>) showing a higher risk compared to the highest quintile (<em>Q5</em>) in both sexes. Body mass index (BMI) and age were independent determinants of ASMM in both sexes, whereas BMI, but interestingly not age, was a determinant of MMV. Moreover, IGF-1 was positively correlated with MMV in both sexes; smoking was negatively correlated with MMV in women. The ACTN3 577XX genotype was only associated with smaller MMV in men.</div></div><div><h3>Conclusion</h3><div>Low MMV increased the risk of sarcopenia, particularly in men. BMI and age strongly influenced ASMM, while MMV was only weakly associated with BMI and not with age. Notably, IGF-1 level was positively associated with MMV only, and ACTN3 genotype was associated to reduced MMV only in men.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142432866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Kidney growth progression patterns in autosomal dominant polycystic kidney disease 常染色体显性多囊肾的肾脏发育模式

IF 4.7 3区医学

Archives of Medical Research Pub Date : 2024-10-10 DOI: 10.1016/j.arcmed.2024.103099

{"title":"Kidney growth progression patterns in autosomal dominant polycystic kidney disease","authors":"","doi":"10.1016/j.arcmed.2024.103099","DOIUrl":"10.1016/j.arcmed.2024.103099","url":null,"abstract":"<div><h3>Background</h3><div>Prognosis for autosomal dominant polycystic kidney disease (ADPKD), the main inherited cause of kidney failure, relies on estimating cystic growth using linear formulas derived from height-adjusted total kidney volume (Ht-TKV). However, nonlinear renal growth patterns may occur in typical ADPKD.</div></div><div><h3>Aims</h3><div>To determine kidney outcomes of subjects diagnosed with typical ADPKD exhibiting nonlinear, and unpredictable cystic growth during follow-up.</div></div><div><h3>Methods</h3><div>Retrospective cohort study. We categorized TKV changes in individuals with typical ADPKD according to observed kidney growth trajectories. Ht-TKV was calculated from consecutive CT or MRI using the ellipsoid method. We compared estimated glomerular filtration rate (eGFR) trajectories with linear mixed models.</div></div><div><h3>Results</h3><div>We included 83 individuals with ADPKD (67% women; age 47 ± 12 years; follow-up 5.2 years [IQR 2.8–9.0]). Three kidney growth patterns were observed: slow progression (24%, <3%/year linear increase), fast progression (39%, ≥3%/year linear increase), and atypical progression (37%, nonlinear growth). Adjusted ht-TKV change in mL/m/year was +1.4 (IQR –4.5 to +10.0), +40.3 (+16.9 to +89.3), and +32.8 (+15.9 to +85.9) for slow, fast, and atypical progressors, respectively (<em>p</em> < 0.001). Atypical progressors exhibited a significantly greater decline in eGFR in mL/min/m²/year (–7.9, 95% CI –6.5, –3.9) compared to slow (–0.5, 95% CI –3.1 to +0.5) and fast progressors (–3.4, 95% CI –7.9, –2.0; between-group <em>p</em> < 0.001). Atypical progressors had a higher proportion of acute complications, including hemorrhages, infections, and urolithiasis (84%), compared to slow (20%) and fast progressors (31%) (<em>p</em> < 0.001).</div></div><div><h3>Conclusion</h3><div>In typical ADPKD, nonlinear, abrupt, and unpredictable cyst growth occurs frequently, leading to a higher risk of acute complications and kidney function decline.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142407337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Theranostics advances in the treatment and diagnosis of neurological and neurosurgical diseases Theranostics 推进了神经和神经外科疾病的治疗和诊断。

IF 4.7 3区医学

Archives of Medical Research Pub Date : 2024-10-05 DOI: 10.1016/j.arcmed.2024.103085

{"title":"Theranostics advances in the treatment and diagnosis of neurological and neurosurgical diseases","authors":"","doi":"10.1016/j.arcmed.2024.103085","DOIUrl":"10.1016/j.arcmed.2024.103085","url":null,"abstract":"<div><div>Theranostics represents a significant advance in the fields of neurology and neurosurgery, offering innovative approaches that combine the diagnosis and treatment of various neurological disorders. This innovation serves as a cornerstone of personalized medicine, where therapeutic strategies are closely integrated with diagnostic tools to enable precise and targeted interventions. Primary research results emphasize the profound impact of theranostics in Neuro Oncol. In this context, it has provided valuable insights into the complexity of the tumor microenvironment and mechanisms of resistance. In addition, in the field of neurodegenerative diseases (NDs), theranostics has facilitated the identification of distinct disease subtypes and novel therapeutic targets. It has also unravelled the intricate pathophysiology underlying conditions such as cerebrovascular disease (CVD) and epilepsy, setting the stage for more refined treatment approaches. As theranostics continues to evolve through ongoing research and refinement, its goals include further advancing the field of precision medicine, developing practical biomarkers for clinical use, and opening doors to new therapeutic opportunities. Nevertheless, the integration of these approaches into clinical settings presents challenges, including ethical considerations, the need for advanced data interpretation, standardization of procedures, and ensuring cost-effectiveness. Despite these obstacles, the promise of theranostics to significantly improve patient outcomes in the fields of neurology and neurosurgery remains a source of optimism for the future of healthcare.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142382743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Follicle-stimulating hormone sweetness: How carbohydrate structures impact on the biological function of the hormone 促卵泡激素的甜味：碳水化合物结构如何影响激素的生物功能。

IF 4.7 3区医学

Archives of Medical Research Pub Date : 2024-10-05 DOI: 10.1016/j.arcmed.2024.103091

{"title":"Follicle-stimulating hormone sweetness: How carbohydrate structures impact on the biological function of the hormone","authors":"","doi":"10.1016/j.arcmed.2024.103091","DOIUrl":"10.1016/j.arcmed.2024.103091","url":null,"abstract":"<div><div>Follicle-stimulating hormone (FSH), or follitropin, exists in multiple molecular forms due largely to its protein-carbohydrate composition and the complexity of the glycans attached to the protein core. The heterogeneity of gonadotropins exists in two forms, macroheterogeneity, which results from the absence of one or two oligosaccharide chains in the ß-subunit, and microheterogeneity which results from variation in the structures and complexity of the glycans attached to the hormone. In the clinical arena, FSH compounds are widely used by fertility specialists to promote ovarian follicle growth and maturation to a preovulatory follicle containing a fertilization-competent oocyte. Several genetically engineered recombinant human FSH preparations have been added to the arsenal of follitropin preparations in several countries for the treatment of infertility, particularly in women attending assisted reproduction clinics. Although the primary structure of these recombinant proteins is identical to that of naturally occurring FSH, the cell context and variations in the production and purification processes may impact the glycosidic profile of the recombinant FSH macro- and micro-heterogeneity, which may potentially influence the pharmacokinetics and pharmacodynamics of the compound. This review concentrates on the structure-function correlates of follitropin, with emphasis on the physiological and biological importance of the carbohydrates attached to its protein core, including its pharmacokinetics and biological activity. Emphasis is placed on pituitary FSH, and the available data on the various recombinant FSH preparations employed in therapeutics are also discussed, considering that this gonadotropin represents the cornerstone for the treatment of infertility in modern assisted reproduction.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142382739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on “Serendipitous adrenal hyperplasia in patients admitted to the emergency department for suspected SARS-CoV-2 infection is linked to increased mortality” 就 "急诊科收治的疑似 SARS-CoV-2 感染者偶然出现的肾上腺增生与死亡率升高有关 "发表评论

IF 4.7 3区医学

Archives of Medical Research Pub Date : 2024-10-05 DOI: 10.1016/j.arcmed.2024.103088

引用次数: 0

Design and implementation of a stakeholder consultation process for rapid health technology assessments in Argentina 阿根廷快速卫生技术评估利益相关者磋商程序的设计与实施。

IF 4.7 3区医学

Archives of Medical Research Pub Date : 2024-10-05 DOI: 10.1016/j.arcmed.2024.103093

{"title":"Design and implementation of a stakeholder consultation process for rapid health technology assessments in Argentina","authors":"","doi":"10.1016/j.arcmed.2024.103093","DOIUrl":"10.1016/j.arcmed.2024.103093","url":null,"abstract":"<div><h3>Introduction</h3><div>Health technology assessment (HTA) is a standardized methodology that allows the assessment technologies’ value. By incorporating the perspective of stakeholders in a public consultation process, transparency and quality of decisions can be improved.</div></div><div><h3>Objective</h3><div>To describe the active stakeholder consultation process for rapid HTAs in an Argentinean, independent, academic, non-profit HTA agency, assessing its initial five years.</div></div><div><h3>Methods</h3><div>Since 2017, we have been conducting an active public consultation process for rapid HTA documents, inviting producers, healthcare professionals, and patient organizations to provide comments, and their input may lead to changes in the HTA documents. Changes were classified as major (changes to the coverage recommendation), intermediate (changes in efficacy, net benefit, or cost-effectiveness that did not change coverage recommendations), and minor modifications (other changes).</div></div><div><h3>Results</h3><div>From May 2017–August 2022, 308 rapid HTA (rHTA) reports were published, and 3,438 invitations were sent. 140 rHTA (45.5%) received a total of 228 comments. Comments came from producers in 53% (<em>n</em> = 112) and healthcare professional organizations in 31.2% (<em>n</em> = 66). Technologies evaluated were drugs in 37% (<em>n</em> = 114), procedures in 35.5% (<em>n</em> = 109), diagnostic methods in 15.3% (<em>n</em> = 47), and devices in 12.2% (<em>n</em> = 38). Out of 308 rHTA documents, 120 (39%) were modified—mostly minor adjustments (<em>n</em> = 100; 80%), followed by major (<em>n</em> = 12; 10%) and intermediate modifications (<em>n</em> = 8; 6.4%).</div></div><div><h3>Conclusion</h3><div>Implementing an active stakeholder involvement process in HTA is feasible in a low- to middle-income country context and strengthens and improves the HTA process.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142382742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0